Abstract #3844

Deferiprone has a dose-dependent effect on liver iron concentration assessed by MRI

Antonella Meloni¹, Vincenzo Positano¹, Gianluca Valeri², Gennaro Restaino³, Chiara Tudisca⁴, Paolo Preziosi⁵, Elisabetta Chiodi⁶, Maria Giovanna Neri¹, Stefano Pulini⁷, Basilia Piraino⁸, Petra Keilberg¹, and Alessia Pepe¹

¹Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy, ²Azienda Ospedaliero-Universitaria Ospedali Riuniti "Umberto I-Lancisi-Salesi", Ancona, Italy, ³Fondazione di Ricerca e Cura "Giovanni Paolo II", Campobasso, Italy, ⁴Policlinico "Paolo Giaccone", Palermo, Italy, ⁵Policlinico “Casilino", Roma, Italy, ⁶Arcispedale “S. Anna”, Ferrara, Italy, ⁷Ospedale Civile “Spirito Santo”, Pescara, Italy, ⁸Policlinico "G. Martino", Messina, Italy

The aim of this multi-centre study was to retrospectively assess in thalassemia major (TM) if deferiprone (DFP) had a dose-dependent effect on liver iron concentration (LIC) assessed by quantitative magnetic resonance imaging (MRI). We found out that the percentage of patients that worsened their status was significantly higher in patients with ≤ 75 mg/kg/d than in patients with > 75 mg/kg/d (26.6% vs 7.7%; P=0.016). So, the worsening in MRI LIC can be prevented by increasing the dose of deferiprone above the widely used regimen of 75 mg/kg body weight.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.